MedTrace Logo

Clinical Study of Bivalirudin for Percutaneous Coronary Intervention (PCI)

NCT03567408 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2018-08-20

No results posted yet for this study

Summary

Bivalirudin is widely used as an anticoagulant to reduce the risk of bleeding in PCI perioperative period. Additionally, 15.7%-32.7% patients have diabetes mellitus who undergo percutaneous coronary interventions (PCI), so bivalirudin was used to anticoagulate in these patients to evaluate its safety and efficacy.

Conditions

Interventions

PROCEDURE

Selective PCI

Selective PCI for treatment of elderly patients (age≥65) presenting with diabetes mellitus.

DRUG

Bivalirudin

Before, during and after surgery, bivalirudin was used according to the dosage regimen to assess it's impact on elderly patients with diabetes mellitus undergoing selective PCI.

Sponsors & Collaborators

  • Qian Gong

    lead OTHER

Principal Investigators

  • Qian Gong, Master · Mian Yang Central Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-15
Primary Completion
2019-08-12
Completion
2020-08-12

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03567408 on ClinicalTrials.gov